Upload
lisa-barker
View
214
Download
0
Tags:
Embed Size (px)
Citation preview
PAIN ASSESSMENT
PATIENT RATES INTENSITY/SEVERITY OF PAIN ON SCALE OF ZERO TO TEN
• LOCATION• QUALITY (ACHING, BURNING,
SHOOTING)• DURATION (INTERMITTENT OR
CONTINUOUS)• WHAT MAKES PAIN BETTER/WORSE
CAUSES OF PHYSICAL PAIN IN CANCER
• Bone Metastases-50%
• Nerve Injury(neuropathic)or compression-25%
• Cancer treatments-19%
TREATMENT OF PHYSICAL PAIN
• TREAT UNDERLYING ILLNESS
• ELEVATE PAIN THRESHOLD
• INTERRUPT PAIN TRANSMISSION
WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF
(“Analgesic Ladder”)
• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:
• STEP 2. MILD OPIOID +/- NON-OPIOID +/-
ADJUVANT If pain persists or worsens, go to:
• STEP 3. STRONG OPIOID +/- NON
OPIOID+/-ADJUVANT
ANALGESIC LADDER
OPIOIDS DO NOT ALWAYS RELIEVE PAIN!
NON-OPIOID ADJUVANTS AND/OR OTHER PAIN METHODS MAY BE NECESSARY.
WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF
(“Analgesic Ladder”)
• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:
• STEP 2. MILD OPIOID +/- NON-OPIOID +/-
ADJUVANT If pain persists or worsens, go to:
• STEP 3. STRONG OPIOID +/- NON
OPIOID+/-ADJUVANT
NON-OPIOID ANALGESIC
PARACETAMOL 500-1000 MG EVERY 4-6 HOURS
• Advantages: Available, cheap,
effective for mild pain.
• Disadvantages: Potential liver toxicity.
Not anti-inflammatory.
Not best choice for bone pain.
NON-OPIOID ANALGESICS
NSAID’S
• Advantages: Anti-inflammatory effects helpful for bone pain. Dosage may be less frequent than paracetamol.• Disadvantages: Potential GI/renal side effects and interference with platelet function.
NSAIDS• SALICYLATES
Aspirin• PROPRIONIC ACIDS
Ibuprofen--every 6 hours; liquid
Naproxen--every 12 hours• ACETIC ACIDS
Diclofenac--every 8 hours
Ketorolac (Toradol)--oral or
parenteral; short term use only
NSAIDS
COX 2 INHIBITORS• Celecoxib
• Less GI toxicity (not perfect);• Less anti-platelet activity• Potential Renal/Cardiovascular Toxicity
OPIOIDS1) CODEINE, MORPHINE
2) SEMISYNTHETIC
HYDROCODONE
BUPRENORPHINE (MIXED AGONIST/
ANTAGONIST)
3) SYNTHETIC
METHADONE (DOLOPHINE)
FENTANYL (DURAGESIC)
TRAMADOL
CONCERNS ABOUT OPIOIDS
1. ADDICTION
Physical Dependence and Psychological Craving
2. TOLERANCE
Rarely a practical problem. Dose can be
increased if tolerance occurs.
3. RESPIRATORY DEPRESSION
Rarely a problem when appropriate dose of oral
narcotic is titrated to level of pain.
CONCERNS ABOUT OPIOIDS
4. LETHARGY Sleepiness may occur in first hours/days but usually improves. 5. NAUSEA Occurs in less than half of patients. May
resolve. 6. CONSTIPATION Frequent problem--should be anticipated with
stool softener/laxative on a daily basis. Avoid bulk laxatives.
WORLD HEALTH ORGANIZATION 3 STEP METHOD FOR CANCER PAIN RELIEF
(“Analgesic Ladder”)
• STEP 1. “NON-OPIOID” +/- ADJUVANT If pain persists or worsens, go to:
• STEP 2. MILD OPIOID +/- NON-OPIOID +/-
ADJUVANT If pain persists or worsens, go to:
• STEP 3. STRONG OPIOID +/- NON
OPIOID+/-ADJUVANT
STEP TWO OPIOIDS
CODEINE
• 30 mg orally is approximately equal in
analgesic effect to 650 mg of aspirin.
• When 30 mg codeine and 650 mg aspirin are combined, the analgesic effect equals or exceeds 60 mg codeine.
•
STEP TWO OPIOIDS
HYDROCODONE
• May be packaged with paracetamol or ibuprofen. Beware of associated toxicity.
STEP TWO OPIOIDS
TRAMADOL
• Synthetic mu agonist opioid
• Reportedly exerts additional analgesic effect by inhibition of serotonin and noradrenaline reuptake.
STEP THREE OPIOIDS(for severe pain)
• MORPHINE
• METHADONE (Dolophine)
• FENTANYL (Duragesic)
• BUPRENORPHINE
STEP THREE OPIOIDS
MORPHINE PROTOTYPE OPIOID SHORT AND LONG-ACTING TABLETS,
LIQUID, CONCENTRATE, SUPPOSITORIES, IV/SUBQ, EPIDURAL, INTRATHECAL
ACTIVE METABOLITES CAN CAUSE TOXICITY IN RENAL FAILURE
STEP THREE OPIOIDS
METHADONE (Dolophine)
• SYNTHETIC• MU AGONIST AND POSSIBLE NMDA
RECEPTOR ANTAGONIST (May help neuropathic pain)
• ORAL/IV/SUBQ
STEP THREE OPIOIDS
METHADONE (Dolophine)
• TRICKY TO TITRATE
VARIABLE CLINICAL EFFECT. (May accumulate and cause lethargy and potential respiratory depression. )
• EFFECTIVE IN LOW DOSES IN SOME PATIENTS WITH POOR RELIEF FROM HIGH DOSE MORPHINE.
STEP THREE OPIOIDS
FENTANYL (Duragesic)
• SHORT-ACTING SYNTHETIC, PACKAGED
AS THREE DAY PATCH
• 25 MCG PATCH APPROXIMATELY
EQUIVALENT TO 15 MG ORAL MORPHINE
• NOT FOR QUICK TITRATION
(ANALGESIC EFFECT PEAKS ABOUT 17 HOURS
AND LINGERS THAT LONG WHEN REMOVED)
• MAY BE ABSORBED QUICKLY IF TEMP
ELEVATION (BEWARE RESPIRATORY
DEPRESSION)
STEP THREE OPIOIDS
BUPRENORPHINE
(sublingual tablet, transdermal patch)
• CAN BE USED FOR MODERATE TO SEVERE PAIN
• MAY INDUCE WITHDRAWAL IN OPIOID DEPENDENT PATIENTS
ANTIDEPRESSANTS
TRICYCLICS amitriptyline(Elavil) nortriptyline(Pamelor) SSRI’s paroxetine(Paxil) Others: venlafaxine (Effexor) mirtazipine (Remeron) duloxetine (Cymbalta)
ANESTHETICS FOR PAIN• Lidocaine IV, Ointment, Lidoderm Patch• EMLA • Ketamine Oral, IV, Subq
OTHER TOPICAL PREPARATIONS• Capsaicin
• SUMMARY
• CANCER PAIN CAN AND MUST BE RELIEVED
• OBTAIN THOROUGH HISTORY AND PHYSICAL EXAM
• ADMINISTER MEDICATION ON A REGULAR BASIS • ACCORDING TO THE ANALGESIC LADDER• STEP 1. NON-OPIOID +/- ADJUVANT• If pain persists or worsens, go to:• STEP 2. MILD OPIOID + NON-OPIOID +/- ADJUVANT• If pain persists or worsens, go to:• STEP 3. STRONG OPIOID +/- NON-OPIOID+/-ADJUVANT• OFFER EMOTIONAL SUPPORT• REASSESS PAIN AND EFFECTIVENESS OF TREATMENT • FREQUENTLY
PAIN SUMMARY
•
•
•
PAIN MUST BE RELIEVED
THOROUGH HISTORY AND PHYSICAL EXAM
MEDICATION ON A REGULAR BASIS ACCORDING TO THE ANALGESIC LADDER
STEP 1. NON-OPIOID +/- ADJUVANT STEP 2. MILD OPIOID +/- NON-OPIOID +/- ADJUVANT STEP 3. STRONG OPIOID +/- NON-OPIOID+/-ADJUVANT
EMOTIONAL SUPPORT
REASSESS PAIN AND EFFECTIVENESS OF TREATMENT FREQUENTLY
OPIOID EQUIVALENCE
5 MG OF OF IV OR SUBQ MORPHINE EVERY 4 HOURS =
15 MG OF IMMEDIATE RELEASE ORAL MORPHINE EVERY 4 HOURS =
25 MCG FENTANYL PATCH EVERY 3 DAYS
USEFUL REFERENCES
• ASSESSING AND TREATING PAIN; UNIPAC THREE, AAHPM, 2012.
• CANCER PAIN RELIEF, WORLD HEALTH ORGANIZATION, GENEVA, 1986.
• EDUCATION FOR END OF LIFE CARE (EPEC) PROJECT,2003; NORTHWESTERN UNIVERSITY SCHOOL OF MEDICINE created with AMA & ROBERT WOOD JOHNSON FOUNDATION, CHICAGO, ILL.
• FERRANTE, FM; ‘‘Principles of Opioid Pharmacotherapy: Practical Implications of Basic Mechanisms”, J. of PAIN and SYMPTOM MANAGEMENT; May 1996, Vol. 11, No 5.
• FOLEY, KM; “The Treatment of Cancer Pain” ,NEJM;1985, 313:84-95.
• MANAGEMENT OF CANCER PAIN, Clinical Practice Guideline #9; AHCPR Publication #94-0592, March 1994.
• PRIMER OF PALLIATIVE CARE, 5th Edition; AAHPM, 2010.